Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 1,723 Shares of Xencor, Inc. (NASDAQ:XNCR)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 13.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,940 shares of the biopharmaceutical company’s stock after purchasing an additional 1,723 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Xencor were worth $343,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in XNCR. GAMMA Investing LLC lifted its stake in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV increased its holdings in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 813 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 949 shares in the last quarter. Point72 DIFC Ltd raised its holdings in shares of Xencor by 10.9% in the 3rd quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 1,333 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,337 shares in the last quarter.

Xencor Trading Up 4.1 %

Shares of NASDAQ XNCR opened at $11.51 on Friday. Xencor, Inc. has a 1 year low of $10.90 and a 1 year high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a 50-day moving average of $15.72 and a 200 day moving average of $20.14. The stock has a market cap of $811.02 million, a P/E ratio of -3.60 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on XNCR shares. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.